Gain Therapeutics, Inc.

GANX · Nasdaq · United States

Share price · GANX

$1.11-0.92 (-45.32%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (1.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GANX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+25.5%
  2. 5 Nov 2026-13.5%

    Nothing announced by GANX that day or the session before.

  3. 26 Oct 2026-8.7%

    Nothing announced by GANX that day or the session before.

  4. 22 Oct 2026+8.4%

    Nothing announced by GANX that day or the session before.

  5. 11 Aug 2026+16.4%
  6. 21 Jul 2026+12.9%

    Nothing announced by GANX that day or the session before.

  7. 29 Jun 2026+13.1%
  8. 28 May 2026+14.1%
  9. 18 Mar 2026-25.6%
  10. 6 Mar 2026+21.5%

    Nothing announced by GANX that day or the session before.

Share of unusual movement by asset

For each asset, the share of GANX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—91%

No dated announcements about its assets since 3 Nov 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
GBA1/glucocerebrosidaseSmall molecule
Parkinson's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
GT-02287Phase 2Parkinson Disease
Est. primary completion 2028-06-30 · NCT07280299 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.4M$12M$3.2M-$3.0M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$2.1M$13M$4.7M-$4.7M operating cash flowreport ↗
2026-Q1—$2.8M$17M$5.6M-$4.7M operating cash flowreport ↗
2025-Q3—$2.9M$8.8M$5.3M-$4.9M operating cash flowreport ↗
2025-Q2—$2.8M$6.7M$5.8M-$5.1M operating cash flowreport ↗
2025-Q1—$2.3M$9.1M$4.5M-$3.8M operating cash flowreport ↗
2024-Q3—$2.6M$12M$4.5M-$6.1M operating cash flowreport ↗
2024-Q2—$4.4M$17M$8.1M-$5.8M operating cash flowreport ↗
2024-Q1—$2.5M$11M+ $2.0M short-term inv.$4.0M-$3.6M operating cash flowreport ↗
2023-Q3—$2.4M$4.3M+ $8.0M short-term inv.$4.7M-$4.0M operating cash flowreport ↗
2023-Q2—$4.0M$6.3M+ $9.9M short-term inv.$7.7M-$5.0M operating cash flowreport ↗
2023-Q1$0.1M$2.8M$6.0M+ $12M short-term inv.$5.1M-$4.2M operating cash flowreport ↗
2022-Q3—$2.0M$11M+ $12M short-term inv.$4.6M-$3.3M operating cash flowreport ↗
2022-Q2$0.1M$2.6M$14M+ $9.9M short-term inv.$5.1M-$5.0M operating cash flowreport ↗
2022-Q1$0.1M$1.6M$34M$3.3M-$2.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$10M$21M$5.0M-$18M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$10M$5.1M-$19M operating cash flowreport ↗
2023-FY$0.1M$12M$12M+ $5.0M short-term inv.$5.6M-$19M operating cash flowreport ↗
2022-FY$0.1M$8.4M$7.3M+ $13M short-term inv.$4.4M-$15M operating cash flowreport ↗
2021-FY$0.2M$7.2M$37M$3.5M-$12M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-29Weidner Jeanette · See RemarksAward / grant (derivative)130,000——Form 4
2026-07-15HASLER HANS PETER · directorAward / grant (derivative)25,000——Form 4
2026-07-15Riley Jeffrey Scott · directorAward / grant (derivative)25,000——Form 4
2026-07-15Melincoff Gwen A · directorAward / grant (derivative)25,000——Form 4
2026-07-15Islam Khalid · directorAward / grant (derivative)25,000——Form 4
2026-07-15Nicaise Claude · directorAward / grant (derivative)25,000——Form 4
2026-07-15GOLDSTEIN DOV A MD · directorAward / grant (derivative)25,000——Form 4
2026-03-24Fuggetta Gianluca · See RemarkAward / grant (derivative)50,000——Form 4